June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
A Toxicological Evaluation of a Single Dose, 90 Day Sustained Release Travoprost Punctum Plug in Canines
Author Affiliations & Notes
  • Arthur Driscoll
    R&D, Ocular Therapeutix, Bedford, MA
  • Charles D Blizzard
    R&D, Ocular Therapeutix, Bedford, MA
  • Ankita Desai
    R&D, Ocular Therapeutix, Bedford, MA
  • Taylor Dickman
    R&D, Ocular Therapeutix, Bedford, MA
  • Michael Bassett
    R&D, Ocular Therapeutix, Bedford, MA
  • Douglas Molla
    R&D, Ocular Therapeutix, Bedford, MA
  • William Cowe
    R&D, Ocular Therapeutix, Bedford, MA
  • Jennifer Wittbold
    R&D, Ocular Therapeutix, Bedford, MA
  • Amar Sawhney
    R&D, Ocular Therapeutix, Bedford, MA
  • Footnotes
    Commercial Relationships Arthur Driscoll, Ocular Therapeutix (E); Charles Blizzard, Ocular Therapeutix (E); Ankita Desai, Ocular Therapeutix (E); Taylor Dickman, Ocular Therapeutix (E); Michael Bassett, Ocular Therapeutix (E); Douglas Molla, Ocular Therapeutix (E); William Cowe, Ocular Therapeutix (E); Jennifer Wittbold, Ocular Therapeutix (E); Amar Sawhney, Ocular Therapeutix (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1993. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Arthur Driscoll, Charles D Blizzard, Ankita Desai, Taylor Dickman, Michael Bassett, Douglas Molla, William Cowe, Jennifer Wittbold, Amar Sawhney; A Toxicological Evaluation of a Single Dose, 90 Day Sustained Release Travoprost Punctum Plug in Canines. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1993.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Pre-clinically evaluate the ocular and systemic toxicity of the Travoprost Punctum Plug (OTX-TP3) following insertion over a 90 day period in dogs.

Methods: OTX-TP3 is a biodegradable hydrogel matrix containing encapsulated travoprost. Upon insertion into the canaliculus, the hydrogel swells to conform to the space enabling plug retention & travoprost release over 90 days. The hydrogel is conjugated with fluorescein to aid visualization. Baseline ophthalmic exams & clinical pathology were conducted. OTX-TP3 was inserted into the vertical canaliculus bilaterally in 16 beagles; a control group (n=16) received a placebo punctum plug & contralaterally a sham insertion procedure. Dosing was ensured (95+%) by replacing lost plugs &/or extending the dosing period. Ophthalmic examinations were performed periodically (slit lamp biomicroscopy, fluorescein staining, fundoscopy, and tonometry). Plasma & tear fluid were collected. Canines were sacrificed at approximately Day 91 of dosing or Day 121 (30 day recovery period) & complete necropsies conducted. Histology was assessed on ocular tissues and nasal turbinates. The study followed FDA 21 CFR, Part 58 GLP for Non Clinical Laboratory Studies.

Results: Punctum plugs were well tolerated overall during the study. A high incidence of punctum plug retention was observed. Systemically, there were no test article-related effects. Posterior segment ophthalmic examinations were similar for all eyes. Consistent with travoprost ocular drops, anterior segment exam findings were limited to mild redness & congestion in the conjunctiva of test article eyes; this was not noted at recovery & not considered adverse. There were no test article related macroscopic observations. All microscopic findings, such as cell infiltration & dilation of the canaliculi, were related to expansion of canalicular tissue from the plugs & resolved during the recovery period. Lack of detectable travoprost in plasma indicated no systemic exposure, while travoprost in tear fluid demonstrated local delivery throughout the dosing period.

Conclusions: The presence OTX-TP3 in the puncta were well tolerated. Results showed no systemic toxicity. A single OTX-TP3 dose demonstrated local drug delivery throughout the course of the study. Clinically, a biodegradable, single dose of sustained release travoprost may offer higher therapy compliance and more convenient alternative to eye drops.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×